Format

Send to

Choose Destination
Cancer Immunol Immunother. 2018 Jan;67(1):135-140. doi: 10.1007/s00262-017-2075-y. Epub 2017 Oct 7.

Safety of shortened infusion times for combined ipilimumab and nivolumab.

Author information

1
Department of Dermatology, Center for Dermatooncology, Eberhard-Karls-University of Tuebingen, Tübingen, Germany.
2
Department of Clinical Pharmacy, Eberhard-Karls-University of Tuebingen, Tübingen, Germany.
3
Department of Dermatology, Center for Dermatooncology, Eberhard-Karls-University of Tuebingen, Tübingen, Germany. andrea.forschner@med.uni-tuebingen.de.

Abstract

BACKGROUND:

Combined ipilimumab and nivolumab induces encouraging response rates in patients with unresectable or metastatic melanoma. However, the approved protocol for dual checkpoint inhibition (3 mg/kg ipilimumab over 90 min and 1 mg/kg nivolumab over 60 min) is time-intensive and several trials have shown that both single agents can be safely administered at faster infusion rates.

AIM:

To investigate whether combined checkpoint inhibition with 3 mg/kg ipilimumab and 1 mg/kg nivolumab can be safely administered over 30 min per agent.

PATIENTS AND METHODS:

We reviewed the rate of infusion-related reactions (IRRs) in the first 12 months of our single-institution experience using shortened infusion times for combined checkpoint inhibition with ipilimumab and nivolumab.

RESULTS:

Between May 24, 2016 and June 10, 2017, a total of 46 melanoma patients received 100 shortened cycles of combined 3 mg/kg ipilimumab and 1 mg/kg nivolumab. One patient (2.2%; 1/46) had a questionable reaction after administration of 1 mg/kg nivolumab over 30 min, but none of the other patients had a bona fide IRR.

CONCLUSIONS:

Shortened infusion times for combined ipilimumab and nivolumab treatment are safe, thereby facilitating a more efficient use of outpatient facilities and enhancing patient's convenience.

KEYWORDS:

Immunotherapy; Infusion rate; Infusion-related reaction; Ipilimumab; Melanoma; Nivolumab

PMID:
28988363
DOI:
10.1007/s00262-017-2075-y
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center